| CHILDREN'S MEDICAL CENTER CORPORATION Patent applications |
| Patent application number | Title | Published |
|---|
| 20120128715 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS - The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist. The immune response induced, or enhanced, in the neonatal host can be, for example, a cytokine immune response and/or a humoral immune response (e.g., antigen-specific). | 05-24-2012 |
| 20120121557 | NEUREGULIN INDUCED PROLIFERATION OF CARDIOMYOCYTES - The present invention provides methods for inducing division of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to repair heart tissue damaged by, for example, myocardial ischemia, hypoxia, stroke, myocardial infarction or chronic ischemic heart disease in vivo. In addition, the methods of the invention can be used to induce heart muscle cells to divide in vitro, in vivo and/or ex vivo, which can then be used in heart tissue repair. | 05-17-2012 |
| 20120121552 | METHODS FOR PURIFYING HEMATOPOIETIC STEM CELLS - Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells. | 05-17-2012 |
| 20120115134 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER - We have discovered a protein in humans, herein referred to as collagen like gene (CLG) product (SEQ ID NOS: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of CLG mRNA expression correlates positively with the metastatic potential of the cancer cell lines tested. | 05-10-2012 |
| 20120114668 | METHOD FOR MODULATING ANGIOGENESIS USING FIBROMODULIN - Described herein are compositions and uses thereof to inhibit or enhance the activity of fibromodulin (FMOD). Such compositions are useful in methods for treatment of age-related macular degeneration involving choroid neovascularization in a subject comprising administering a therapeutically effective amount of a fibromodulin activity inhibitor to the subject. | 05-10-2012 |
| 20120107403 | BLADDER RECONSTRUCTION - The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of the luminal organ or tissue structure with a first cell population on or in a first area and a second cell population such as a smooth muscle cell population in a second area of the polymeric matrix. The method involves grafting the device to an area in a patient in need of treatment. The polymeric matrix comprises a biocompatible and biodegradable material. | 05-03-2012 |
| 20120101067 | METHODS FOR ENHANCING HEMATOPOIETIC PROGENITOR CELL ENGRAFTMENT - Described herein are methods for improving engraftment of hematopoietic cells in an individual following hematopoietic progenitor cell transplantation (e.g., via bone marrow or cord blood transplantation). Methods for increasing hematopoietic progenitor cell proliferation in individuals with bone marrow aplasia are also described. The methods involve administering an agent that inhibits adipogenesis, adipocyte growth, adipocyte differentiation and/or adipocyte proliferation. | 04-26-2012 |
| 20120083689 | LIGHT-GUIDED TRANSLUMINAL CATHETER - Generally, the present invention is directed to a light-guided catheter for direct visualization of placement through the skin. An embodiment of the invention includes a method for transcutaneous viewing and guiding of intracorporeal catheters into a body that comprises inserting a catheter into the body having at least one lumen and internally illuminating the catheter with light capable of propagating through the blood and tissue to an external viewer outside of the body. | 04-05-2012 |
| 20120058099 | USE OF HYPOXANTHINE FOR PROMOTION OF NEURONAL OUTGROWTH - Disclosed herein is a method of promoting neuronal outgrowth in a neuron. The method comprises contacting the neuron with an effective amount of hypoxanthine, to thereby promote neuronal outgrowth of the neuron. The hypoxanthine may be contacted in the absence of xanthine oxidase and/or in the absence of exogenous nerve growth factor (NGF), and/or in the absence of exogenous D-mannose, and/or in the absence of exogenous oncomodulin, and/or in the absence of exogenous TGF-B. The neuron may be an optic nerve neuron or a retinal neuron and/or an injured neuron. Neurons may be from the central nervous system (CNS) or the peripheral nervous system (PNS). The methods are useful for treating an injured neuron, for example to an optic nerve neuron, resulting from branch and central vein/artery occlusion, trauma, edema, angle-closure glaucoma, open-angle glaucoma. Methods of treatment of various neurological injuries and diseases, as well as therapeutic compositions, are also disclosed. | 03-08-2012 |
| 20120045472 | Biochemically Stabilized HIV-1 ENV Trimer Vaccine - Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. | 02-23-2012 |
| 20120028268 | METHOD OF PREDICTING ACUTE APPENDICITIS - Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals. | 02-02-2012 |
| 20120020953 | DIAGNOSIS AND TREATMENT OF CANCER - Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof. | 01-26-2012 |
| 20110306555 | BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament. | 12-15-2011 |
| 20110305676 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation. | 12-15-2011 |
| 20110300154 | TREATMENT OF AIRWAY HYPERREACTIVITY - The invention provides strategies for treating and preventing airway hyperreactivity and non-allergic asthma comprising antagonizing IL-17 activity and/or production by iNKT cells. Provided herein is a method of diagnosing non-allergic asthma and airway hyperreactivity comprising neutrophils quantification in sputum. | 12-08-2011 |
| 20110293582 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation. | 12-01-2011 |
| 20110281759 | METHOD FOR DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides methods of diagnosing and/or predicting autism spectrum disorder comprising determining the presence of microdeletions and microduplications on chromosomes 15 and 16. | 11-17-2011 |
| 20110268736 | METHOD FOR TREATING CONGENITAL MYOPATHY - The invention relates to methods and compositions for therapy for congenital myopathies. | 11-03-2011 |
| 20110256526 | DETECTION OF HUMAN SOMATIC CELL REPROGRAMMING - The methods and kits described herein are based, in part, to the discovery phenotype representing a fully-reprogrammed iPS cell and several reprogramming intermediates. The methods and kits described herein permit identification of fully-reprogrammed iPS cells and further permits one of skill in the art to monitor the emergence of iPS cells during the reprogramming process. The methods/kits can also be performed using real time using live cell imaging. Also described herein are methods for screening candidate reprogramming agents by monitoring the emergence of fully-reprogrammed iPS cells in the presence and absence of such an agent. | 10-20-2011 |
| 20110250585 | ORGAN MIMIC DEVICE WITH MICROCHANNELS AND METHODS OF USE AND MANUFACTURING THEREOF - System and method includes a body having a central microchannel separated by one or more porous membranes. The membranes are configured to divide the central microchannel into a two or more parallel central microchannels, wherein one or more first fluids are applied through the first central microchannel and one or more second fluids are applied through the second or more central microchannels. The surfaces of each porous membrane can be coated with cell adhesive molecules to support the attachment of cells and promote their organization into tissues on the upper and lower surface of the membrane. The pores may be large enough to only permit exchange of gases and small chemicals, or to permit migration and transchannel passage of large proteins and whole living cells. Fluid pressure, flow and channel geometry also may be varied to apply a desired mechanical force to one or both tissue layers. | 10-13-2011 |
| 20110230568 | HEATING OF POLYMERS AND OTHER MATERIALS USING RADIATION FOR DRUG DELIVERY AND OTHER APPLICATIONS - The present invention generally relates to systems and methods for releasing a releasable species from an article using an external trigger, for example, using infrared or near-infrared radiation. Such systems and methods may be useful, for example in biological applications (e.g., as an implant within a subject), industrial applications, commercial applications, or the like. One aspect of the invention is generally directed to an article containing a radiation-sensitive polymer or other radiation-sensitive material. Exposure of the radiation-sensitive material to radiation such as infrared or near-infrared radiation may cause the material to increase in temperature. This increase in temperature may be used, in some cases, to cause the release of a drug or other releasable species from the article. For instance, a drug may be contained in a heat-sensitive material positioned in thermal communication with the radiation-sensitive material, or a drug may be contained within an enclosure that is isolated, at least in part, by a heat-sensitive material positioned in thermal communication with the radiation-sensitive material. In another aspect of the invention, a receive antenna may be used to focus infrared or near- infrared radiation on an article. For instance, the receive antenna may focus infrared or near-infrared radiation on a radiation-sensitive material in the article. Such focusing may be useful, in some embodiments, to control release of a drug or other releasable species from the article. Other aspects of the invention are directed to systems and methods of making or using such articles, e.g., by implanting the article within a subject, methods of treatment involving such articles, kits including such articles, and the like. | 09-22-2011 |
| 20110212163 | MAGNETIC HEATING FOR DRUG DELIVERY AND OTHER APPLICATIONS - The present invention generally relates to systems and methods for releasing a compound from an article using an external trigger, for example, magnetic fields. One aspect of the invention is generally directed to an article containing a magnetically-susceptible material. Exposure of the magnetically-susceptible material to a magnetic field, such as an oscillating magnetic field, may cause the magnetically-susceptible material to increase in temperature. This increase in temperature may be used, in some embodiments, to cause the release of a drug or other releasable material from the article. For instance, the drug may be contained in a heat-sensitive material in thermal communication with the magnetically-susceptible material, or the drug may be contained within an enclosure that is isolated, at least in part, by a heat-sensitive material in thermal communication with the magnetically-susceptible material. Other aspects of the invention are directed to systems and methods of making or using such articles, e.g., by implanting the article within a subject, methods of treatment involving such articles, kits including such articles, or the like. | 09-01-2011 |
| 20110212027 | RADIATIVE HEATING FOR DRUG DELIVERY AND OTHER APPLICATIONS - The present invention generally relates to systems and methods for releasing a releasable species from an article using an external trigger, for example, using microwave radiation or other forms of radiation, e.g., radiofrequency radiation. Such systems and methods may be useful, for example, in biological applications (e.g., as an implant within a subject), industrial applications, commercial applications, or the like. One aspect of the invention is generally directed to an article containing a radiation-sensitive polymer or other radiation-sensitive material. Exposure of the radiation- sensitive material to radiation such as microwave and/or radiofrequency radiation may cause the material to increase in temperature. This increase in temperature may be used, in some cases, to cause the release of a drug or other releasable species from the article. For instance, a drug may be contained in a heat-sensitive material positioned in thermal communication with the radiation-sensitive material, or a drug may be contained within an enclosure that is isolated, at least in part, by a heat-sensitive material positioned in thermal communication with the radiation-sensitive material. In another aspect of the invention, a receive antenna, such as a microwave receive antenna may be used to focus microwave and/or radiofrequency radiation on an article. For instance, the receive antenna may focus microwave and/or radiofrequency radiation on a radiation-sensitive material in the article. Such focusing may be useful, in some embodiments, to control release of a drug or other releasable species from the article. Other aspects of the invention are directed to systems and methods of making or using such articles, e.g., by implanting the article within a subject, methods of treatment involving such articles, kits including such articles, and the like. | 09-01-2011 |
| 20110206716 | SYNERGISTIC IMMUNOGENIC FUSION PROTEIN-POLYSACCHARIDE CONJUGATE - An immunogenic composition comprising a fusion protein-polysaccharide conjugate consisting of a polysaccharide (PS) or pneumococcal bacterial cell wall polysaccharide (CWPS) conjugated to X:PdT where PdT represents the nonhemolytic variant of pneumolysin and X represents an antigenic peptide or protein of interest is provided. The immunity to X is synergistically enhanced by the fusion conjugate. Methods of protecting a subject from pneumococcal colonization or disease by administering an immunogenic composition including a fusion protein (PsaA:PdT) containing truncated PsaA and the nonhemolytic variant of pneumolysin (PdT) conjugated with CWPS (PsaA:PdT-CWPS) is also provided. | 08-25-2011 |
| 20110190210 | PROMININ-1 PEPTIDE FRAGMENTS AND USES THEREOF - Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration. | 08-04-2011 |
| 20110183899 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY - The invention relates to methods and compositions for the treatment of obesity. The methods and compositions relate to the use of an agent that reduces or prevents endoplasmic reticulum stress in conjunction with leptin. | 07-28-2011 |
| 20110182867 | MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES - The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies. | 07-28-2011 |
| 20110166060 | TYMPANIC MEMBRANE PERMEATING EAR DROPS AND USES THEREOF - The present invention provides compositions and methods for noninvasive delivery of therapeutic agents across an intact tympanic membrane. For example, the compositions include a penetration enhancer which increases the flux of a therapeutic agent (e.g., antibiotic) across the tympanic membrane. Such compositions are particularly useful in the treatment of otitis media. Additionally, the composition may include a sustained release agents that, in some embodiments form sustained release reservoirs, in situ, once administered to a patient. | 07-07-2011 |
| 20110159040 | NOVEL IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF - An aspect of the present invention provides for methods for identifying novel immunogens that when administered as vaccines elicit a cellular or humoral immunogenic response. In a particular embodiment, a method identified pneumococcal T-cell immunogens that elicit systemic IL-17A responses, and reduce or protect against pneumococcal colonization. | 06-30-2011 |
| 20110151447 | METHOD TO PRODUCE INDUCED PLURIPOTENT STEM (IPS) CELLS FROM NON-EMBRYONIC HUMAN CELLS - The invention provides methods for generating induced pluripotent stem (iPS) cells from normal and mutant adult cells, as well as the iPS cells so generated from such methods. In some aspects, iPS cells are generated by ectopically expressing SOX2 and OCT4 nucleic acids in such adult cells. Other nucleic acids such as but not limited to MYC may also be ectopically expressed in such adult cells in the methods described herein. | 06-23-2011 |
| 20110150894 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 - The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via β1 integrin activation. | 06-23-2011 |
| 20110104725 | Method of Effecting Coagulation in a Droplet - The invention provides techniques for coagulating blood on a droplet actuator. The invention also provides methods of manipulating the coagulated blood including a variety of droplet operations that may be conducted using the coagulated blood. Further, the invention provides a variety of assays that make use of the coagulated blood or various blood samples as input. | 05-05-2011 |
| 20110086922 | SENSORY-SPECIFIC LOCAL ANESTHESIA AND PROLONGED DURATION LOCAL ANESTHESIA - Combinations of charged local anesthetics with chemical permeation enhancers have been developed to give long duration block which is selective for sensory block over motor block. The duration of block is greatly prolonged by combining the local anesthetic with a permeation enhancer. The selectivity of sensory over motor block is provided by selecting the concentration of the local anesthetic and the permeation enhancer to provide selective permeability of the sensory and motor neurons to the enhancer. | 04-14-2011 |
| 20110086041 | Fusion-Intermediate State of HIV-1 gP41 Targeted by Broadly Neutralizing Antibodies - Isolated, antigenic polypeptides including a prehairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a prehairpin intermediate conformation of gp41 and methods of making antibodies a that bind to prehairpin intermediate conformation of gp41 are also provided. Vaccines against a prehairpin intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, prehairpin intermediate conformation of gp41 are further provided. | 04-14-2011 |
| 20110071088 | METHOD FOR TREATING NEUROLOGICAL DISORDERS - The present invention is based on the discovery that suppressing the activity of the Nogo receptor (NgR) alone does not result in extensive axon regeneration unless the intrinsic growth program of neurons is also activated. Accordingly, the present invention is directed to methods of stimulating axon regeneration using a combination therapy wherein agents that inhibit NgR activity or downstream pathways activated by inhibitory signals are combined with agents that activate the growth pathway of neurons (e.g. polypeptide growth factors, activators of macrophages, purine nucleosides, or hexoses). | 03-24-2011 |
| 20110061120 | SELF-CLEAVING RIBOZYMES AND USES THEREOF - In certain embodiments, the disclosure relates to compositions and methods relating to a ribozyme-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to schistosome self-cleaving RNA mutant motifs. | 03-10-2011 |
| 20110059152 | AUGMENTATION OF ORGAN FUNCTION - The present invention provides methods and compositions for augmenting organ functions using small-scale matrix implants generated by seeding tissue-specific or undifferentiated cells onto a matrix materials (e.g., a wafer, sponge, or hydrogel). The seeded matrix composition can then be implanted and will develop into an organ-supplementing structure in vivo. Continued growth and differentiation of the seeded cells on the implanted matrix results in the formation of a primitive vascular system in the tissue. The primitive vascular system can then develop into a mature vascular system, and can also support the growth and development of additional cultured cell populations. The seeded matrix system can be used to introduce a variety of different cells and tissues in vivo. | 03-10-2011 |
| 20110054306 | TISSUE CLIP - A tissue clip for adjoining tissues including a body portion, a biasing mechanism interconnecting the body portion to a tissue grasping mechanism, the grasping mechanism having a first condition wherein the grasping mechanism is extending against and away from the body portion and a second condition wherein the grasping mechanism is biased against the body portion. A tissue clip and deployer combination. A method of interconnecting tissue by deploying the tissue clip, puncturing tissue to be interconnected with the tissue clip, and interconnecting the tissue. A method of treating an aneurism by deploying the tissue clip at an aneurism site, closing off the aneurism site with the tissue clip, and treating the aneurism. A method of imaging a surgical procedure with ultrasound by modifying a surface of a metal surgical instrument, and imaging the metal surgical instrument with ultrasound during a surgical procedure. | 03-03-2011 |
| 20110052570 | METHOD TO PROGNOSE RESPONSE TO ANTI-EGFR THERAPEUTICS - The present invention provides methods to determine the likelihood of effectiveness of an EGFR targeting treatment in a subject affected with a tumor based on the expression of EGFR of endothelial cells associated with the tumor. The present invention also provides methods of treating a subject affected with, or at risk for developing cancer with an EGFR targeting treatment and methods to screen for an EGFR targeting treatment. | 03-03-2011 |
| 20110028561 | PROTECTION OF NEURAL RETINA BY REDUCTION OF ROD METABOLISM - Described herein are methods for treatment or prevention of retinal dysfuntion by reduction of rod cell energy demand. Particular embodiments include methods for improving rod-mediated retinal function in a developing retina by administering an agent that reduces energy demand in the rod cell. Such agents that target rod cell energy demand can be administered to a subject at risk for retinal dysfunction to modify rod-cell function, such that the retina reaches retinal maturity. Also described herein are methods for suppressing the visual cycle in a developing rod cell by contacting the cell with an agent that reduces the energy demand of the rod cell. | 02-03-2011 |
| 20110027338 | BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament. | 02-03-2011 |
| 20110020326 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASE - The present invention is directed toward methods for treating, inhibiting the progression of or eradicating polycystic kidney disease in a mammal in need thereof by providing a cMET inhibitor. | 01-27-2011 |
| 20110009370 | METHOD TO ENHANCE TISSUE REGENERATION - The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect. | 01-13-2011 |
| 20100278792 | METHOD OF ENHANCING PROLIFERATION AND/OR HEMATOPOIETIC DIFFERENTIATION OF STEM CELLS - The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. The method of the present invention comprises increasing the intracellular level of a cdx in stem cells, including hematopoietic stem cells, in culture, either by providing an exogenous cdx protein to the cell, or by introduction into the cell of a genetic construct encoding a cdx. The cdx is selected from the cdx family and includes cdx1, cdx2, or cdx4. The cdx may be a wild type protein appropriate for the species from which the cells are derived, or a mutant form of the protein. | 11-04-2010 |
| 20100267140 | SOLUBLE INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND USE THEREOF - The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF | 10-21-2010 |
| 20100249025 | PEPTIDE ANTAGONISTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR - The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity. | 09-30-2010 |
| 20100239637 | CONTACT LENS DRUG DELIVERY DEVICE - The present invention relates generally to devices and methods for administering one or more active agents to the eye of a human or animal patient in need thereof, and more particularly to devices for application to the cornea which release active agent to the eye in a controlled manner. | 09-23-2010 |
| 20100227823 | METHODS FOR REGULATING ANGIOGENESIS AND VASCULAR INTEGRITY USING TRK RECEPTOR LIGANDS - The present invention relates to methods of inducing or inhibiting the angiogenic process and promoting vessel growth or stabilization in an organ by modulating the trk receptor pathway. The present invention also relates to a method for treating a pathological disorder in a patient which includes administering a trk receptor ligand or an inhibitor or expression or activity of a trk receptor ligand. The present invention also relates to a method of screening for a modulator of angiogenesis, vessel growth, or vessel stabilization. Another aspect of the present invention is a method of diagnosing or monitoring a pathological disorder in a patient which includes determining the presence or amount of a trk receptor ligand or activation of a trk receptor ligand in a biological sample. | 09-09-2010 |
| 20100222371 | PREVENTION OF SURGICAL ADHESIONS - The present invention relates to methods for treatment (particularly the prevention or suppression) of formation or reformation of adhesions, particularly in the peritoneal or pelvic cavities resulting from wound, surgery, infection, inflammation or trauma. The invention provides methods useful for inhibiting, suppressing or ameliorating adhesion formation in mammals, including humans wherein an individual is administered a compound selected from the group consisting of sunitinib malate, axitinib, semaxanib, sorafenib, ZD1839, and erlotinib. The invention applies to human and veterinary applications. The inventive method has been shown to be especially effective in preventing adhesion formation in the peritoneum following surgery. | 09-02-2010 |
| 20100221266 | METHODS TO REGULATE MIRNA PROCESSING BY TARGETING LIN-28 - The present invention relates generally to methods to regulate microRNA (miRNA) biogenesis, in particular the regulation of the processing of pri-miRNA to mature miRNA by Lin-28 and/or variants such as Lin28B. In particular, the present invention relates to methods and compositions comprising at least one agent which inhibits Lin-28 function or activity and/or expression to increase the processing of pri-mRNA to mature miRNA. More specifically, one aspect of the invention is directed to treating and/or preventing cancer in a subject by administering an agent that inhibits Lin-28 activity or expression to a subject, preferably a human subject. | 09-02-2010 |
| 20100209396 | Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells - The present invention provides methods for inducing differentiation of a stem cell, such as an embryonic stem cell, into a hematopoietic stem cell, by expressing a cdx gene and/or a hox gene. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. | 08-19-2010 |
| 20100203143 | SYSTEMS AND METHODS FOR NANOMAGNETIC ACTUATION OF MOLECULAR CELL SIGNALING - The present invention relates to signaling mechanisms that transduce magnetic inputs into physiological cellular outputs. More particularly, the present invention relates to systems and methods for non-invasively controlling cellular signaling functions and behaviors by harnessing receptor-mediated and intracellular molecular-mediated signal transduction using nanomagnetic cellular switches. | 08-12-2010 |
| 20100158855 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. | 06-24-2010 |
| 20100152704 | Method for Intravesical Drug Delivery - Implant devices for intravesical administration and local drug delivery. The device has a body which includes a hollow tube formed of a biocompatible material; at least one reservoir in the tube which contains a drug; and one or more apertures through which the drug can be released. The device is configured for minimally invasive insertion into a body cavity, such as the bladder. The hollow tube may be elastomeric to permit the device to be elastically deformed from its initial shape into an elongated shape for passage through a catheter, where following such passage the device can return to or toward its initial shape to facilitate retention of the device in the body cavity. The body may have a narrow, elongated shape effective to permit insertion of the drug delivery device through a catheter without necessarily deforming the body, yet include flexible projections which effect retention within the body cavity. | 06-17-2010 |
| 20100144603 | METHODS AND USES THEREOF OF PROSAPOSIN - The invention relates to methods for treating of tumor metastasis, methods for preventing, inhibiting, and predicting tumor recurrence and tumor metastasis, and methods of preventing cancer development for one at risk of developing cancer, for one diagnosed with a benign cancer, and/or for one diagnosed with malignant cancer. The invention also relates to methods of treating angiogenesis-dependent diseases and disorders. In addition, the invention provides: (1) a method for screening for tumor/cancer derived angiogenesis and metastasis factors; (2) a method for screening for compounds that inhibit angiogenesis and metastasis; (3) a method for screening for compounds that promote anti-angiogenesis and anti-metastasis activities; (4) a method for cancer prognosis evaluation; (5) a method for predicting the tissue specificity of a metastatic cancer; (6) a method for determining likelihood of metastasis; and (7) a method for cancer prognosis evaluation by the surveillance of metastasis development. | 06-10-2010 |
| 20100111924 | Chromosomal Modification Involving the Induction of Double-Stranded DNA Cleavage and Homologous Recombination at the Cleavage Site - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases. | 05-06-2010 |
| 20100111894 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. | 05-06-2010 |
| 20100105151 | Novel Druggable Regions in the Dengue Virus Envelope Glycoprotein and Methods of Using the Same - The present invention relates to novel druggable regions discovered in dengue virus envelope glycoprotein, or dengue virus E protein, which is a class II viral E protein. The present invention further relates to methods of using the druggable regions to screen potential candidate therapeutics for diseases caused by viruses having class II E proteins, e.g. viral fusion inhibitors. | 04-29-2010 |
| 20100105136 | CHIMERIC T-CELL RECEPTORS AND T-CELLS TARGETING EGFRVIII ON TUMORS - Chimeric T-cell receptor proteins have been produced in cells by the construction of nucleic acids and vectors, and the transfection of the vectors into cells. The chimeric proteins comprise, as an extracellular binding portion, a single chain antibody portion that binds to EGFRvIII, a transmembrane portion derived from human CD8α or CD28, and an intracellular signaling portion derived from human CD3ζ. The invention includes nucleic acids, vectors and cells associated with the production of the chimeric membrane protein, as well as methods to treat rumors bearing EGFRvIII, a mutant epidermal growth factor receptor. | 04-29-2010 |
| 20100105071 | METHODS FOR PREDICTING THE ONSET OF MENARCHE - Embodiments of the invention provide methods for predicting the onset of menarche, i.e. a females first menstrual period, through the measurement of salivary hormone levels (e.g. 17-β estradiol, testosterone, progesterone, and/or 17 hydroxy-progesterone (17-OHP)). In particular, the methods described herein enable a reliable determination that menarche will, or will not occur, within varied time intervals, e.g. 1 to 30 days, 1 to 45 days, 1 to 60 days and 1 to 90 days. Diagnostic kits and products of manufacture comprising the kits are also provided. | 04-29-2010 |
| 20100069251 | METHODS FOR PRODUCING EMBRYONIC STEM CELLS FROM PARTHENOGENETIC EMBRYOS - Means for producing embryonic stem (pES) cells which have a heterozygous genome that is matched to an individual donor are provided. In one embodiment, a means for the generation and isolation of parthenogenetic embryonic stem (pES) cells which have regions of heterozygosity that are fully matched to the oocyte donor at the MHC loci (e.g. (h-)p(MI)ES cells is provided. This is in contrast to the traditional methods of parthenogenesis that generate parthenogenetic embryonic stem (pES) cells having a substantially homozygous haploidentical set of chromosomes that are homozygous at the MHC loci. | 03-18-2010 |
| 20100048862 | Ferroportin1 nucleic acids, proteins, antibodies and methods - Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel multiple-transmembrane domain protein, expressed in the yolk sac. Zebrafish ferroportin1 is required for the transport of iron from maternally-derived yolk stores to the circulation, and functions as an iron exporter when expressed in | 02-25-2010 |
| 20100048705 | METHODS OF TREATING AND PREVENTING NEOVASCULARIZATION WITH OMEGA-3 POLYUNSATURATED FATTY ACIDS - Disclosed are methods for treating or preventing ocular neovascularization in a subject at risk. The method comprises administering to the subject an effective amount of omega-3 polyunsaturated fatty acid to thereby treat or prevent the ocular neovascularization. This method is suitable for treating or preventing retinopathy of prematurity, retina vein occlusion, sickle cell retinopathy, choroidal neovascularization, radiation retinopathy, microangiopathy, retinal hyperoxia, diabetic retinopathy, and age related macular degeneration. Preferably the methods are applied to premature infants, especially those exposed to high levels of oxygen, to treat or prevent ocular neovascularization results from retinopathy of prematurity. Preferably, the omega-3 polyunsaturated fatty acid is administered at high dose, periodically (e.g. from birth) over a prolonged period of time, until the eye is fully vascularized, or to the age of 1 year. Appropriate routes of administration include oral and intravenous administration. Suitable omega-3 polyunsaturated fatty acids include docosahexaenoic acid and eicosapentaenoic acid. These agents can be administered in a pharmaceutically acceptable carrier, e.g. one which contains an anti-oxidant for the omega-3 polyunsaturated fatty acid. | 02-25-2010 |
| 20100040584 | METHODS FOR PROMOTING NEOVASCULARIZATION - The success of tissue engineering and therapeutic neovascularization depends on the development of a microvascular network. The present invention provides methods for promoting neovascularization in tissue engineering constructs, tissue repair, and wound healing comprising endothelial and mesenchymal progenitor cells. | 02-18-2010 |
| 20100035843 | METHODS FOR ATTENUATING ALLERGEN-INDUCED AIRWAY HYPERREACTIVITY USING CD1D DEPENDENT ANTAGONISTS - The present invention is directed to a method of inhibiting allergen-induced airway CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Methods of the invention are useful for treatment and prevention of air-way hyperactivity caused by an allergen, and results in the attenuation of CD1d-restricted immune responses, including treatment of hay fever and asthma are due to air-way hyperactivity, and for systemic administration to attenuate ongoing immune responses. Preferably, these compositions are in a form intended for administration via nasal passages or directly inhaled to the air-ways. | 02-11-2010 |
| 20100003297 | Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues - A method is provided for local controlled delivery of a drug to the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens of a patient in need of treatment. In one embodiment, the method includes implanting a resorbable drug delivery device within the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens of the patient. The drug delivery device may include an elastic device body housing at least one drug reservoir which contains at least one drug. In a preferred embodiment, the method further includes releasing the drug from the device in a controlled manner to, typically directly to, the seminal vesicle, the prostate, the ejaculatory duct, or the vas deferens. | 01-07-2010 |
| 20090322783 | Method and apparatus for displaying information - A method for displaying large amounts of information. The method includes the steps of forming a spatial layout of tiles each corresponding to a representative reference element; mapping observed elements onto the spatial layout of tiles of representative reference elements; assigning a respective value to each respective tile of the spatial layout of the representative elements; and displaying an image of the spatial layout of tiles of representative elements. Each tile includes atomic attributes of representative elements. The invention also relates to an apparatus for displaying large amounts of information. The apparatus includes a tiler forming a spatial layout of tiles, each corresponding to a representative reference element; a comparator mapping observed elements onto said spatial layout of tiles of representative reference elements; an assigner assigning a respective value to each respective tile of said spatial layout of representative reference elements; and a display displaying an image of the spatial layout of tiles of representative reference elements. | 12-31-2009 |
| 20090312405 | Methods to Predict and Prevent Resistance to Taxoid Compounds - Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided. | 12-17-2009 |
| 20090306776 | METHODS AND PROCEDURES FOR LIGAMENT REPAIR - Methods and devices for the repair of a ruptured ligament using a scaffold device are provided. Aspects of the invention, may include a scaffold attached by a suture to an anchor. In aspects of the invention, the anchor may be secured to a bone near or at the repair site. | 12-10-2009 |
| 20090306181 | Compositions and methods for evaluating and treating heart failure - The invention relates to compositions, formulations, kits, and methods useful for the treatment and evaluation of heart disease in an individual. | 12-10-2009 |
| 20090285786 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH - The present invention provides for compositions and methods for modulating hematopoietic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo. | 11-19-2009 |
| 20090280130 | METHOD FOR THE TREATMENT OF ANTHRAX TOXICITY - is a spore-forming Gram positive bacterium that is the causative agent of anthrax infection. Vascular leakage and pleural effusions are hallmarks of the fulminant phase of human anthrax disease following infection. The present invention provides a method of halting, treating, and preventing the rapid toxic effects of human anthrax disease by blocking the VEGF pathway with chemical inhibitors of the VEGFR signaling pathway. The invention is also applicable as an anti-anthrax therapeutic in bio-warfare defense. | 11-12-2009 |
| 20090263464 | BLADDER RECONSTRUCTION - The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of the luminal organ or tissue structure with a first cell population on or in a first area and a second cell population such as a smooth muscle cell population in a second area of the polymeric matrix. The method involves grafting the device to an area in a patient in need of treatment. The polymeric matrix comprises a biocompatible and biodegradable material. | 10-22-2009 |
| 20090257953 | NOVEL FLUORINE-18 LABELED RHODAMINE DERIVATIVES FOR MYOCARDIAL PERFUSION IMAGING WITH POSITRON EMISSION TOMOGRAPHY - The present invention is directed toward novel fluorine-18 labeled rhodamine dye derivatives and methods of making the same. The present invention is also directed toward methods of using novel fluorine-18 labeled rhodamine dye derivatives as positron emission tomography imaging agents and myocardial perfusion imaging agents. | 10-15-2009 |
| 20090254104 | METHODS AND COLLAGEN PRODUCTS FOR TISSUE REPAIR - Methods and devices for the repair of articular tissue using collagen material are provided. Compositions of collagen material and related kits are also provided. | 10-08-2009 |
| 20090221533 | METHOD OF TREATING FATTY LIVER DISEASE - The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestional operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor. | 09-03-2009 |
| 20090220994 | METHODS FOR DIAGNOSIS OF CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME - The present invention relates to methods for diagnosis of chronic prostatitis/chronic pain pelvic syndrome (CP/CPPS). We have found specific biomarkers that are present in higher concentrations in patients that have chronic prostatitis/chronic pain pelvic syndrome (CP/CPPS) as compared to subjects that have no symptoms of CP/CPPS. In particular, uromodulin (THP), aminopeptidase N (AMPN), dipeptidylpeptidase IV (CD26), neprilysin (NEP), zinc-α-2-glycoprotein (ZA2G) and alkaline phosphatase (ALP) were found to be present at higher concentrations in CP/CPPS patient urine that is voided after prostatic message. Accordingly, the invention is directed to methods for diagnosis of CP/CPPS by monitoring the levels of at least one of these proteins in post-prostatic massage urine, as well as to diagnostic kits designed for diagnosis of CP/CPPS. | 09-03-2009 |
| 20090220433 | Novel biotinylated compositions - Novel biotinylated composition comprising a nucleic acid, e.g. siRNA, that are useful for targeting therapeutic and imaging agents to sites of infection and tumors are disclosed. | 09-03-2009 |
| 20090203590 | METHOD FOR THE INHIBITION OF ANGIOGENESIS - The present invention is based on the discovery that Matrilin-1 has antiangiogenic and anticancer properties. The invention is directed to a method of treating a disease that responds to an inhibition of angiogenesis. Additionally, the invention can be applied to those at risk for developing a disease that responds to an inhibition of angiogenesis. The methods comprise administering to a mammal an effective angiogenesis-inhibiting amount of an Matrilin-1 consisting of Matrilin-1, Matrilin-1 fragment, analog, or derivative that is administered in a composition substantially free of other cartilage proteins. | 08-13-2009 |
| 20090203014 | METHOD FOR DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides methods of diagnosing and/or predicting autism spectrum disorder comprising determining the presence of microdeletions and microduplications on chromosomes 15 and 16. | 08-13-2009 |
| 20090191244 | MICROBUBBLES AND METHODS FOR OXYGEN DELIVERY - Compositions containing a carrier and microbubles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope formed of at least one base lipid and at least one emulsifying agent. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 mL oxygen/dL suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and/or one or more tissues or organs. The microbubbles may be administered alone or in combination with other treatments as an adjuctive therapy. | 07-30-2009 |
| 20090181420 | Inhibiting Smad signaling promotes neuron regeneration - Regeneration of a lesioned CNS axon of a mature neuron, determined to be subject to regeneration inhibition by Smad2/3 signaling, is promoted by contacting the neuron with an inhibitor of Smad2/3 signaling sufficient to promote regeneration of the axon. | 07-16-2009 |
| 20090176874 | TNP-470 POLYMER CONJUGATES AND USE THEREOF - The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa. | 07-09-2009 |
| 20090176226 | METHOD FOR DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides methods of diagnosing and/or predicting autism spectrum disorder comprising determining the presence of microdeletions and microduplications on chromosomes 15 and 16. | 07-09-2009 |
| 20090136489 | METHODS FOR THE TREATMENT, DIAGNOSIS, AND PROGNOSIS OF CANCER - We have discovered that antizyme inhibitor (AZI) is expressed at increased levels in highly proliferating cells. We have also discovered that inhibiting antizyme inhibitor, including inhibiting its expression, reduces the growth of cancer cells. The present invention is directed to the use of inhibitors of antizyme inhibitor for the treatment of cancer, the use of antizyme inhibitor for the diagnosis and prognosis of cancer, and methods for identifying novel cancer treatments. | 05-28-2009 |
| 20090118343 | TREATMENT OF SEVERE DISTAL COLITIS - This invention relates to methods and materials involved in the treatment of diseases with severe distal colitis component, and more specifically non-fungal and/or non-microbial induced mucositis of the distal intestinal tract. Kits and pharmaceutical compositions for medical treatments also are provided. | 05-07-2009 |
| 20090104604 | SPERM-SPECIFIC CATION CHANNEL, CATSPER2, AND USES THEREFOR - Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (CatSper2) are disclosed. The CatSper2 protein is shown to be specifically expressed in sperm. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the CatSper2 gene and protein are disclosed. Also provided are methods of in vitro fertilization and contraception, methods of identifying modulators of CatSper2 activity, methods of genotyping subjects with respect to CatSper2, methods of diagnosing and treating CatSper2-mediated disorders, including infertility, as well as methods of doing business related to CatSper2-mediated disorders. | 04-23-2009 |
| 20090092652 | Method for the inhibition of angiogenesis or cancer using protective antigen related molecules - The present invention is based on the discovery that protective antigen related molecules (PARMs) without anthrax lethal factor have antiangiogenic or anticancer properties. The invention is directed to a method of inhibiting an angiogenic disease/disorder or cancer. Additionally, the invention can be applied to those at risk for developing cancer or an angiogenic disease/disorder comprising administering to a mammal an angiogenesis-inhibiting or cancer inhibiting amount of an PARM (including analogs, or derivative thereof having angiogenesis-inhibiting or anticancer activity, consisting of PA, PA fragment, analog, or derivative that is administered in a composition substantially free of anthrax lethal factor or other toxins). | 04-09-2009 |
| 20090082858 | Transcatheter Delivery of a Replacement Heart Valve - A replacement heart valve apparatus. The heart valve apparatus includes a stent and a valve frame having a substantially cylindrical body defining a lumen. The valve frame includes a plurality of curved wire pairs attached to the substantially cylindrical body. Each curved wire pair includes an inner curved wire and an outer curved wire. The wire frame further having a plurality of leaflets. Each leaflet is attached to a respective inner curved wire and extends over a respective outer curved wire, so as to position the body of the leaflet within the lumen of the valve frame. | 03-26-2009 |
| 20090054975 | DEPLOYMENT DEVICE FOR CARDIAC SURGERY - A deployment device for deploying a material into a patient, said deployment device having a housing and a placement device including a retracted condition within the housing for holding a material, in a collapsed condition, within the housing and an extended condition from the housing for disposing and releasing the material at a predetermined site in an uncollapsed condition. A method of deploying a material by placing the placement device in an extended condition and affixing the material to the extended placement device, retracting the placement device into the housing with the material in a collapsed condition, extending the placement device, and placing the material at a predetermined site in an uncollapsed condition. | 02-26-2009 |
| 20090053284 | MEDICAL DEVICES FOR USE IN THE SURGICAL TREATMENT OF HYPERPROLIFERATIVE DISEASES AFFECTING THE SPINAL CORD - Provided herein are new methods for the treatment of hyperproliferative diseases affecting the spinal cord, including the use of biodegradable polymers to treat spinal cord tumor recessing, i.e., to patch open zones left by spinal tumor removal. Biocompatible polymeric materials are tailored to fill areas previously occupied by tumors, e.g., materials in the form of tubular articles configured for insertion into the spinal column after surgical removal of a tumor. These protective articles may also include medicinal agents that stimulate spinal column neural regeneration, such as medicines or donor neuronal cells such as human neural stem cells, thus assisting patients to recover motorsensory function after spinal tumor surgery. | 02-26-2009 |
| 20090042229 | PLATELET BIOMARKERS FOR CANCER - The present invention relates to the fields of immunology and biochemistry. Particularly, the present invention describes methods, devices and kits for early detection of clinical conditions having associated changes in systemic angiogenic activity, particularly cancers, inflammatory conditions, infections, and events associated with pregnancy and abortion. | 02-12-2009 |
| 20090029920 | Methods and Compositions for Treating Ocular Disorders - The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine. | 01-29-2009 |
| 20090022862 | Method to limit acrylamide in heated foods - The present invention provides a method for reducing the level of acrylamide in a food product, comprising: (a) applying an acrylamide reduction agent in alkaline solution onto a food material before heat treating the food material; and (b) heat treating the food material to form the finished food product, wherein due to application of the thiol agent in alkaline solution, the finished food product comprises reduced level of acrylamide compared to a product which has not been treated with the acrylamide reduction agent in alkaline solution before heating. In addition, the present invention provides a food production produced by the method of the present invention. | 01-22-2009 |
| 20090012376 | Continuous Analyte Monitor and Method of Using Same - The use of an analyte-monitoring device for continuously monitoring analytes within a bodily fluid bypass flow path. A method of monitoring analytes in a patient by continuously monitoring analytes present in a bodily fluid of that patient within the bodily fluid bypass flow path is provided. | 01-08-2009 |
| 20080275119 | Treatment and Prevention of Liver Disease Associated with Parenteral Nutrition (PN) - The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method for treating or preventing liver disease in a human patient obtaining nutritional support through PN. The method comprises intravenous administration of an effective amount of an omega-3-fatty acid emulsion to the patient, wherein the patient is not administered phytosterols or plant derived fatty acids, e.g. omega-6 fatty acids derived from a plant source, and wherein the administration of the omega-3-fatty acid emulsion to the patient is for a period greater than three weeks. Preferably, the administration is for a period of greater than six weeks. More preferably, the administration is for a period greater than three months. | 11-06-2008 |
| 20080274077 | Method for Treating Neurological Disorders - The present invention is based on the discovery that suppressing the activity of the Nogo receptor (NgR) alone does not result in extensive axon regeneration unless the intrinsic growth program of neurons is also activated Accordingly, the present invention is directed to methods of stimulating axon regeneration using a combination therapy wherein agents that inhibit NgR activity or downstream pathways activated by inhibitory signals are combined with agents that activate the growth pathway of neurons (e.g. polypeptide growth factors, activators of macrophages, purine nucleosides, or hexoses). | 11-06-2008 |
| 20080268463 | Methods for Prognosis and Diagnosis of Chronic Prostatitis/Pelvic Pain Syndrome and Interstitial Cystitis - We have discovered that levels of specific protein biomarkers present in urine samples of subjects correlate with the presence, or absence of, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men or interstitial cystitis (IC) in women. These protein biomarkers are cortitropin releasing hormone (CRH), dehydroepiandrosterone (DHEA), neuropeptide Y (NPY) and Galanin. Accordingly, the invention is directed to methods for diagnosis of CP/CPPS and IC by monitoring the levels of at least one of these proteins in urine, as well as to diagnostic kits designed for diagnosis of CP/CPPS and IC. | 10-30-2008 |
| 20080261867 | Soluble inhibitors of vascular endothelial growth factor and use thereof - The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF | 10-23-2008 |
| 20080248030 | Method of Treating Angiogenic Diseases - The present invention relates to methods for treating cancer comprising administering an anti-VEGF (vascular endothelial growth factor) monoclonal antibody (e.g. Avastin) and a N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-TNP-470 conjugate (e.g. Caplostatin) to a patient in need thereof. | 10-09-2008 |
